Search General Info
Search Education
Search Partnering Companies

Joshua Liang

Shanghai, China
As CEO of Clover Biopharmaceuticals, Joshua Liang oversees all company operations and strategy. He brings the critical global expertise needed to accelerate Clover’s development as an emerging leader in the biopharmaceutical industry. Since joining Clover in 2016, he has raised about USD $700 million in total capital, grown the full-time employee headcount from 20 to more than 500 and initiated Clover’s first clinical trials in Australia and China. In addition to co-inventing Clover’s COVID-19 S-Trimer vaccine, Joshua has led critical partnership activities with Dynavax and the Coalition for Epidemic Preparedness Innovations (CEPI) in the development of the S-Trimer COVID-19 vaccine candidate based on Clover’s proprietary Trimer-Tag© technology.
Prior to joining Clover, Joshua was a biotechnology investment banker at Centerview Partners in San Francisco where he worked on transactions of more than USD $20 billion in total. Joshua was trained in biological research having co-authored multiple original research papers in peer-reviewed journals. He has a Bachelor of Science in economics from the Wharton School as well as a Bachelor of Arts in biology from the University of Pennsylvania, having graduated from the Roy & Diana Vagelos Program in Life Sciences & Management.
Speaking In
11:05 AM - 11:50 AM (EDT)
Tuesday, June 15

Vaccines have gone from under the radar to everywhere in the mind of the public and many new…